Neion Bio, a biotechnology company revolutionizing the production of biologic medicines, today announced the close of an oversubscribed $23 million Series A financing to further advance its novel ...
Management expects cash burn to hold steady through 2026 and start declining by the end of next year, driven by increasing Attruby revenues and improved operating leverage. Kumar said, "Our current ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results